Abstract
Thirteen single-agent and 23 combination chemotherapeutic regimen trials using ifosfamide involving 1,326 evaluable patients with non-small cell lung cancer were reviewed. From these studies, several conclusions can be drawn: (1) Ifosfamide as a single agent shows response rates greater than 20%; (2) in combination with cisplatin, with or without a third drug, ifosfamide induces response rates of 38%; however, survival is not increased significantly; (3) other combinations with ifosfamide have a response rate greater than 35%; and (4) ifosfamide warrants continued evaluation and testing in combination with other effective agents.
Original language | English (US) |
---|---|
Pages (from-to) | 31-38 |
Number of pages | 8 |
Journal | Seminars in oncology |
Volume | 16 |
Issue number | 1 SUPPL. 3 |
State | Published - Jan 1 1989 |
ASJC Scopus subject areas
- Hematology
- Oncology